{"id":390137,"date":"2020-12-08T00:00:00","date_gmt":"2020-12-08T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfim0005-2020-biopharma-graft-versus-host-disease-niche-rare-disease-landscape-forecast-us-eu5-2020\/"},"modified":"2026-03-31T10:44:12","modified_gmt":"2026-03-31T10:44:12","slug":"nrlfim0005-2020-biopharma-graft-versus-host-disease-niche-rare-disease-landscape-forecast-us-eu5-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfim0005-2020-biopharma-graft-versus-host-disease-niche-rare-disease-landscape-forecast-us-eu5-2020\/","title":{"rendered":"Graft Versus Host Disease | Niche &#038; Rare Disease Landscape &#038; Forecast | US\/EU5 | 2020"},"content":{"rendered":"<p>Graft versus host disease (GVHD) is a potentially life-threatening complication of allogeneic hematopoietic stem-cell transplantation (HSCT). GVHD is a systemic inflammatory reaction triggered by donor T cells\u2019 recognition of host cell antigens in nontarget tissue as foreign. For decades, steroids have been the first-line therapy for the prevention and treatment of GVHD, but interviewed experts call for better treatments for steroid-refractory patients, as well as better first-line and prophylactic treatments for GVHD. Although development in this space has historically been slow, the pipeline for GVHD therapies is now robust with a number of late-phase agents, including Mesoblast\u2019s Ryoncil (remestemcel-L), Incyte\u2019s itacitinib, Kadmon\u2019s belumosudil, Elsalys \/ Mediolanum&#8217;s Leukotac (inolimomab), and Xenikos&#8217;s T-Guard. Here, we examine the clinical and commercial opportunity of these emerging therapies and how they may affect the commercial performance of current therapies, such as AbbVie \/ Janssen\u2019s Imbruvica and Incyte \/ Novartis\u2019s Jakafi \/ Jakavi.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>How large is the GVHD population, and how will it change through 2029? What percentage of the GVHD population receives drug treatment?<\/li>\n<li>How is GVHD currently managed in the United States and EU5? How well does the GVHD pipeline align with unmet needs in the space?<\/li>\n<li>Which emerging therapies do experts consider most promising? If approved, how would emerging therapies affect the management of GVHD? Which emerging drugs hold the most commercial potential?<\/li>\n<li>What are some of the key GVHD market drivers and constraints? How will continuing advances in patient and host human leukocyte antigen (HLA) matching affect the market?<\/li>\n<\/ul>\n<p>CONTENT HIGHLIGHTS<\/p>\n<ul>\n<li>Geographies: United States and EU5.<\/li>\n<li>Primary research: Six country-specific interviews with thought-leading GVHD specialists, supported by survey data collected for this study.<\/li>\n<li>Epidemiology: Diagnosed incident cases of acute and chronic GVHD, diagnosed incident cases of acute GVHD by grade, drug-treated cases of GVHD by country.<\/li>\n<li>Forecast: Drug-level sales and patient share of key GVHD therapies in 2029.<\/li>\n<li>Emerging therapies: Late phase \/ preregistered: 6 drugs; Phase II: >10 drugs; coverage of select preclinical and Phase I products.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390137","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-graft-versus-host-disease","biopharma-geography-us","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390137","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390137\/revisions"}],"predecessor-version":[{"id":576469,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390137\/revisions\/576469"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390137"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}